One limitation to the failure of BMDSCs to improve glomerulonephritis in our study is the use of only one bolus dose after one week of anti-Thy1 injection as well as using i.v. route of administration which might not be the proper way for target trafficking of BMDSCs to the kidney to promote glomerular healing. This evidence concerns the gene THY1 and glomerulonephritis.